

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
5 January 2017 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 7:45 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the November 2016 meeting:

- ***Designated Newly-Approved Drugs***
 - ***Pulmonary IIs—Long-Acting Muscarinic Antagonists (LAMAs):
tiotropium soft mist inhaler (Spiriva Respimat)***
- ***Drug Class Reviews***
 - ***Oral Anticoagulants***
 - ***Antilipidemics-1 (LIP-1s)—Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors***
- ***Innovator Drugs***
 - ***Antiemetics: aprepitant oral suspension (Emend)***
 - ***Antigout Agents: lesinurad (Zurampic)***
 - ***Antihemophilic Agents: von Willebrand factor (Vonvendi)***
 - ***Antiplatelet Agents: aspirin/omeprazole (Yosprala)***
 - ***Beta Blocker Combination Antihypertensive Agents: nebivolol/valsartan (Byvalson)***
 - ***LAMA/Long-Acting Beta Agonists (LABA) combinations:
glycopyrrolate/formoterol oral inhaler (Bevespi Aerosphere)***
 - ***Miscellaneous Cardiovascular Agents: nitroglycerin sublingual powder (GoNitro)***
 - ***Multiple Sclerosis Drugs: daclizumab (Zinbryta)***

- *Ophthalmic Anti-Inflammatory Immunomodulatory Agents: lifitegrast ophthalmic solution (Xiidra)*
- *Opioid-Induced Constipation Drugs: methylnaltrexone tablets (Relistor)*
- *Oral Contraceptives: norethindrone/ethinyl estradiol/iron (Taytulla)*
- *Renin-Angiotensin Antihypertensive Agents (RAAs): lisinopril oral solution (Qbrelis)*
- *Topical Otic Antibiotic/Steroid Combinations: ciprofloxacin/fluocinolone acetonide otic solution (Otovel)*
- **Utilization Management Issues**
 - **Prior Authorization Criteria**
 - *Basal Insulins: insulin degludec (Tresiba)*
 - *Analgesics and Combinations: butalbital/acetaminophen/caffeine tablets (Allzital)*
 - *Targeted Immunomodulatory Biologics (TIBs): adalimumab (Humira) and ustekinumab (Stelara)*
 - *Ophthalmic Anti-inflammatory/Immunomodulatory Agents—Ophthalmic Immunomodulatory Agents: cyclosporine 0.05% ophthalmic emulsion (Restasis)*
 - *Oral Oncology Agents: crizotinib (Xalkori)*
- **Formulary Update**
 - *Non-Insulin Diabetes Drugs—DPP-4 Inhibitors: linagliptin/metformin XR (Jentadueto XR)*
- **National Defense Authorization Act 2008, Section 703 Actions**
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.